<p>Harrow, Inc.（纳斯达克代码：HROW - 获取免费报告）在目前覆盖该股票的十家券商中获得了 “适度买入” 的共识评级，Marketbeat Ratings 报告称。一位分析师对该股票给予了卖出建议，一位给予了持有建议，八位则对该公司发布了买入建议。在过去一年中，发布报告的券商对该股票的平均 12 个月目标价为 71.4286 美元。</p>
<p>几位股票分析师最近对 HROW 股票发布了报告。Zacks Research 在 9 月 12 日的研究报告中将 Harrow 的评级从 “强力买入” 下调至 “持有”。Weiss Ratings 在 10 月 8 日的研究报告中重申了对 Harrow 股票的 “卖出（e+）” 评级。Craig Hallum 在 9 月 23 日的研究报告中将 Harrow 的目标价从 54.00 美元上调至 64.00 美元，并给予该股票 “买入” 评级。BTIG Research 在 9 月 24 日的研究报告中重申了 “买入” 评级，并对 Harrow 股票发布了 63.00 美元的目标价。最后，LADENBURG THALM/SH SH 在 11 月 12 日的报告中将 Harrow 股票的目标价从 64.00 美元上调至 66.00 美元，并给予该公司 “买入” 评级。</p>
<p><strong>阅读我们最新的 Harrow 股票分析</strong></p>
<h2>机构资金流入和流出</h2>
<p>一些大型投资者最近调整了对该公司的持股。德克萨斯州教师退休系统在第二季度将其在 Harrow 的持股增加了 4.1%。德克萨斯州教师退休系统目前拥有 8,478 股该公司的股票，价值 259,000 美元，此前在上个季度购买了 332 股。制造商人寿保险公司在第二季度将其在 Harrow 的持股增加了 2.1%。制造商人寿保险公司目前拥有 16,547 股该公司的股票，价值 505,000 美元，此前在上个季度购买了 341 股。Alliancebernstein L.P. 在第三季度将其在 Harrow 的持股增加了 1.7%。Alliancebernstein L.P. 目前拥有 29,520 股该公司的股票，价值 1,422,000 美元，此前在此期间购买了 500 股。Pale Fire Capital SE 在第二季度将其在 Harrow 的持股增加了 6.8%。Pale Fire Capital SE 目前拥有 8,683 股该公司的股票，价值 265,000 美元，此前在上个季度购买了 550 股。最后，MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 在第一季度将其在 Harrow 的持股增加了 4.6%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 目前拥有 18,146 股该公司的股票，价值 483,000 美元，此前在此期间购买了 790 股。目前 72.76% 的股票由机构投资者持有。</p>
<h2>Harrow 股票表现</h2>
<p>Harrow（纳斯达克代码：HROW）周一开盘价为 50.09 美元。该公司的 50 日移动平均线为 41.78 美元，200 日移动平均线为 38.83 美元。Harrow 的 12 个月低点为 20.85 美元，12 个月高点为 51.30 美元。该公司的流动比率为 2.72，速动比率为 2.52，债务与股本比率为 5.21。该股票的市值为 18.6 亿美元，市盈率为-500.85，贝塔值为 0.07。</p>
<p>Harrow（纳斯达克代码：HROW - 获取免费报告）最后一次公布季度财报是在 11 月 10 日，报告显示该公司每股收益（EPS）为 0.33 美元，超出分析师共识预期的 0.22 美元，超出幅度为 0.11 美元。Harrow 的净利润率为-1.99%，股本回报率为 28.71%。该公司季度收入为 7164 万美元，而分析师预期为 7370 万美元。平均而言，股票研究分析师预测 Harrow 在当前财年将发布-0.53 的每股收益。</p>
<h2>关于 Harrow</h2>
<p>（获取免费报告）</p>
<p>Harrow Health, Inc.（纳斯达克代码：HROW）是一家总部位于美国的商业阶段生物制药公司，专注于眼科治疗和诊断。该公司专注于开发、制造和分销专有、仿制和品牌眼科产品，旨在治疗多种眼部疾病，包括青光眼、眼内压增高、干眼症和其他前段疾病。</p>
<p>通过其全资附属公司 ImprimisRx，Harrow Health 提供直接面向医生的定制配方模型以及低成本的仿制药替代品。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票比 Harrow 更好</li>
<li>请勿删除，立即阅读</li>
<li>富人如何退休</li>
<li>投资者警报：微型 “3 美元 AI 奇迹股票” 即将爆发</li>
<li>100 万美元在退休中能维持多久？</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SFJPVw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SFJPVw"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在 Harrow 吗？</h2>
<p>在考虑 Harrow 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Harrow 并不在名单上。</p>
<p>虽然 Harrow 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

HROW

<p>Harrow, Inc.（纳斯达克代码：HROW）获得了十家券商的共识评级为 “适度买入”。一位分析师将其评级为卖出，一位为持有，八位为买入。12 个月的平均目标价格为 71.43 美元。最近的报告显示，Zacks 将其评级下调至持有，而 Craig Hallum 和 BTIG Research 则分别给予了 64.00 美元和 63.00 美元的买入评级。Harrow 的股票开盘价为 50.09 美元，市值为 18.6 亿美元，最近的每股收益为 0.33 美元，超出预期。该公司专注于眼科治疗和诊断</p>

<p>Harrow, Inc. (NASDAQ:HROW - Get Free Report) has been given a consensus rating of &#34;Moderate Buy&#34; by the ten brokerages that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and eight have issued a buy recommendation on the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $71.4286.</p>
<div class="lb-trans"><p>Harrow, Inc.（纳斯达克代码：HROW - 获取免费报告）在目前覆盖该股票的十家券商中获得了 “适度买入” 的共识评级，Marketbeat Ratings 报告称。一位分析师对该股票给予了卖出建议，一位给予了持有建议，八位则对该公司发布了买入建议。在过去一年中，发布报告的券商对该股票的平均 12 个月目标价为 71.4286 美元。</p>
</div><p>Several equities analysts have recently issued reports on HROW shares. Zacks Research lowered Harrow from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research note on Friday, September 12th. Weiss Ratings reiterated a &#34;sell (e+)&#34; rating on shares of Harrow in a research report on Wednesday, October 8th. Craig Hallum boosted their target price on Harrow from $54.00 to $64.00 and gave the stock a &#34;buy&#34; rating in a research note on Tuesday, September 23rd. BTIG Research restated a &#34;buy&#34; rating and issued a $63.00 price target on shares of Harrow in a research note on Wednesday, September 24th. Finally, LADENBURG THALM/SH SH lifted their price target on shares of Harrow from $64.00 to $66.00 and gave the company a &#34;buy&#34; rating in a report on Wednesday, November 12th.</p>
<div class="lb-trans"><p>几位股票分析师最近对 HROW 股票发布了报告。Zacks Research 在 9 月 12 日的研究报告中将 Harrow 的评级从 “强力买入” 下调至 “持有”。Weiss Ratings 在 10 月 8 日的研究报告中重申了对 Harrow 股票的 “卖出（e+）” 评级。Craig Hallum 在 9 月 23 日的研究报告中将 Harrow 的目标价从 54.00 美元上调至 64.00 美元，并给予该股票 “买入” 评级。BTIG Research 在 9 月 24 日的研究报告中重申了 “买入” 评级，并对 Harrow 股票发布了 63.00 美元的目标价。最后，LADENBURG THALM/SH SH 在 11 月 12 日的报告中将 Harrow 股票的目标价从 64.00 美元上调至 66.00 美元，并给予该公司 “买入” 评级。</p>
</div><p><strong>Read Our Latest Stock Analysis on Harrow</strong></p>
<div class="lb-trans"><p><strong>阅读我们最新的 Harrow 股票分析</strong></p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>A number of large investors have recently modified their holdings of the company. Teacher Retirement System of Texas increased its holdings in Harrow by 4.1% in the 2nd quarter. Teacher Retirement System of Texas now owns 8,478 shares of the company's stock worth $259,000 after purchasing an additional 332 shares in the last quarter. The Manufacturers Life Insurance Company grew its holdings in shares of Harrow by 2.1% during the second quarter. The Manufacturers Life Insurance Company now owns 16,547 shares of the company's stock worth $505,000 after purchasing an additional 341 shares during the last quarter. Alliancebernstein L.P. increased its stake in shares of Harrow by 1.7% in the third quarter. Alliancebernstein L.P. now owns 29,520 shares of the company's stock valued at $1,422,000 after buying an additional 500 shares during the period. Pale Fire Capital SE raised its holdings in Harrow by 6.8% in the 2nd quarter. Pale Fire Capital SE now owns 8,683 shares of the company's stock valued at $265,000 after buying an additional 550 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Harrow by 4.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 18,146 shares of the company's stock worth $483,000 after buying an additional 790 shares during the period. 72.76% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>一些大型投资者最近调整了对该公司的持股。德克萨斯州教师退休系统在第二季度将其在 Harrow 的持股增加了 4.1%。德克萨斯州教师退休系统目前拥有 8,478 股该公司的股票，价值 259,000 美元，此前在上个季度购买了 332 股。制造商人寿保险公司在第二季度将其在 Harrow 的持股增加了 2.1%。制造商人寿保险公司目前拥有 16,547 股该公司的股票，价值 505,000 美元，此前在上个季度购买了 341 股。Alliancebernstein L.P. 在第三季度将其在 Harrow 的持股增加了 1.7%。Alliancebernstein L.P. 目前拥有 29,520 股该公司的股票，价值 1,422,000 美元，此前在此期间购买了 500 股。Pale Fire Capital SE 在第二季度将其在 Harrow 的持股增加了 6.8%。Pale Fire Capital SE 目前拥有 8,683 股该公司的股票，价值 265,000 美元，此前在上个季度购买了 550 股。最后，MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 在第一季度将其在 Harrow 的持股增加了 4.6%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 目前拥有 18,146 股该公司的股票，价值 483,000 美元，此前在此期间购买了 790 股。目前 72.76% 的股票由机构投资者持有。</p>
</div><h2>Harrow Price Performance</h2>
<div class="lb-trans"><h2>Harrow 股票表现</h2>
</div><p>Shares of NASDAQ:HROW opened at $50.09 on Monday. The firm has a 50 day moving average of $41.78 and a 200-day moving average of $38.83. Harrow has a 12 month low of $20.85 and a 12 month high of $51.30. The company has a current ratio of 2.72, a quick ratio of 2.52 and a debt-to-equity ratio of 5.21. The stock has a market capitalization of $1.86 billion, a PE ratio of -500.85 and a beta of 0.07.</p>
<div class="lb-trans"><p>Harrow（纳斯达克代码：HROW）周一开盘价为 50.09 美元。该公司的 50 日移动平均线为 41.78 美元，200 日移动平均线为 38.83 美元。Harrow 的 12 个月低点为 20.85 美元，12 个月高点为 51.30 美元。该公司的流动比率为 2.72，速动比率为 2.52，债务与股本比率为 5.21。该股票的市值为 18.6 亿美元，市盈率为-500.85，贝塔值为 0.07。</p>
</div><p>Harrow (NASDAQ:HROW - Get Free Report) last announced its quarterly earnings data on Monday, November 10th. The company reported $0.33 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.22 by $0.11. Harrow had a negative net margin of 1.99% and a positive return on equity of 28.71%. The business had revenue of $71.64 million for the quarter, compared to analysts' expectations of $73.70 million. On average, equities research analysts predict that Harrow will post -0.53 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Harrow（纳斯达克代码：HROW - 获取免费报告）最后一次公布季度财报是在 11 月 10 日，报告显示该公司每股收益（EPS）为 0.33 美元，超出分析师共识预期的 0.22 美元，超出幅度为 0.11 美元。Harrow 的净利润率为-1.99%，股本回报率为 28.71%。该公司季度收入为 7164 万美元，而分析师预期为 7370 万美元。平均而言，股票研究分析师预测 Harrow 在当前财年将发布-0.53 的每股收益。</p>
</div><h2>About Harrow</h2>
<div class="lb-trans"><h2>关于 Harrow</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Harrow Health, Inc NASDAQ: HROW is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.</p>
<div class="lb-trans"><p>Harrow Health, Inc.（纳斯达克代码：HROW）是一家总部位于美国的商业阶段生物制药公司，专注于眼科治疗和诊断。该公司专注于开发、制造和分销专有、仿制和品牌眼科产品，旨在治疗多种眼部疾病，包括青光眼、眼内压增高、干眼症和其他前段疾病。</p>
</div><p>Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.</p>
<div class="lb-trans"><p>通过其全资附属公司 ImprimisRx，Harrow Health 提供直接面向医生的定制配方模型以及低成本的仿制药替代品。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Harrow</li>
<li>Do not delete, read immediately</li>
<li>How the Rich Retire</li>
<li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li>
<li>How Long Will $1M Last in Retirement?</li>
<li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Harrow 更好</li>
<li>请勿删除，立即阅读</li>
<li>富人如何退休</li>
<li>投资者警报：微型 “3 美元 AI 奇迹股票” 即将爆发</li>
<li>100 万美元在退休中能维持多久？</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SFJPVw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=HROW"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Harrow Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Harrow 吗？</h2>
</div><p>Before you consider Harrow, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Harrow 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Harrow wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Harrow 并不在名单上。</p>
</div><p>While Harrow currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Harrow 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Harrow 公司（NASDAQ:HROW）被分析师一致评级为 “适度买入”